Oncolytic Virus Cancer Therapy Market to Grow Positively at a Paltry CAGR During the Study Period, DelveInsight | Targovax, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amg

DelveInsight's "Oncolytic Virus Cancer Therapy - Market Insight, Epidemiology and Market Forecast - 2034" report provides current treatment practices, emerging drugs, Oncolytic Virus Cancer Therapy market share of the individual therapies, current and forecasted Oncolytic Virus Cancer Therapy market size from 2020 to 2034 segmented by seven major markets. The report also offers current Oncolytic Virus Cancer Therapy therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Oncolytic Virus Cancer Therapy market.
Download our latest report @ https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key highlights from the Oncolytic Virus Cancer Therapy Market Report:
The United States dominates the oncolytic virus market, representing over 70% of the total market, significantly outpacing the EU4 countries (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Oncolytic viruses offer several advantages over other tumor immunotherapies, including high efficacy, precise targeting, and fewer side effects or issues with drug resistance.
Currently, there are two approved oncolytic virus therapies: IMLYGIC (Talimogene laherparepvec/T-VEC) from Amgen, approved in the US, Europe, and Japan in 2015, and DELYTACT (teserpaturev/G47∆) from Daiichi Sankyo, approved in Japan in 2021.
The pipeline for oncolytic viruses is strong, with leading pharmaceutical companies such as Replimune, Genelux, Imugene, and EpicentRx actively advancing research to improve cancer treatment options. Among emerging therapies, RP1 is anticipated to capture approximately 40% of the market in the next decade due to its promising efficacy.
In November 2023, Genelux received Fast Track designation from the US FDA for Olvi-Vec (olvimulogene nanivacirepvec) to treat patients with platinum-resistant or refractory ovarian cancer.

Oncolytic Virus Cancer Therapy Overview
Oncolytic viruses are a class of anti-cancer agents designed to induce tumor regression by selectively replicating within tumor cells, causing immunogenic cell death, and enhancing the host's antitumor immune response. These viruses, which can be either native or genetically modified, target and destroy cancer cells.

Although the exact mechanisms are not fully understood, oncolytic viruses primarily exert their effects through two main processes: directly lysing infected tumor cells (oncolysis) and indirectly boosting the host's antitumor immunity.

Oncolytic viruses can be classified into RNA and DNA types. RNA viruses, such as reoviruses, paramyxoviruses, and picornaviruses, typically encode only a few genes, allowing for rapid replication and destruction of tumor cells. In contrast, DNA oncolytic viruses, including herpesviruses, adenoviruses, and poxviruses, can accommodate multiple foreign genes but generally have slower replication and amplification rates.
In the next decade, oncolytic virus therapies are poised to significantly impact the pharmaceutical sector, with substantial potential in treating cancers such as brain, skin, and prostate cancers. Recent advancements have enabled these therapies to reach notable therapeutic milestones.

Oncolytic viruses represent a cutting-edge approach in cancer treatment, leveraging natural or engineered viruses to specifically target and destroy malignant cells while leaving healthy tissue unharmed. These viruses demonstrate exceptional tumor selectivity by exploiting the unique vulnerabilities of cancer cells.

The therapeutic mechanism of oncolytic viruses involves a dual action: first, the selective infection and destruction of tumor cells, followed by the stimulation of a robust antitumor immune response. This process includes the replication of the virus within cancer cells, leading to cell lysis and the release of new viral particles, which then spread to neighboring cancer cells, perpetuating the cycle of destruction.

Overall, oncolytic virus therapies offer a promising multifaceted approach, combining direct tumor targeting with immune system activation to enhance the fight against cancer.
To know more about the advancements in the oncolytic virus cancer therapy, visit: https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Oncolytic Virus Cancer Therapy Epidemiological Insights
According to GLOBOCAN, the incidence of breast cancer in the United States is projected to increase from 274,375 cases in 2022 to 321,295 cases by 2035.
DelveInsight's analysis reveals that, in 2023, prostate cancer represented approximately 20% of the total patient pool targeted by oncolytic virus therapies across the 7MM.
Currently, melanoma is the primary focus for oncolytic virus therapies, but it is anticipated that Non-Melanoma Skin Cancer will become the leading target in the future.
In 2023, melanoma accounted for about 10% of the total new cancer cases in the 7MM.
Oncolytic Virus Cancer Therapy Treatment Market
As cancer remains a leading cause of death worldwide, there is an increasing drive to develop innovative therapies capable of effectively targeting and destroying cancer cells. Oncolytic viruses, known for their ability to selectively infect and replicate within tumor cells, have emerged as a promising option in cancer treatment. The growth of this market is fueled by heightened research and development, increased investments from pharmaceutical companies, and an expanding pipeline of clinical trials.

With continued advancements and strategic partnerships, oncolytic viruses are set to play a crucial role in the future of oncology. They offer new hope for patients and are paving the way for more effective and personalized cancer treatments.

In 2015, IMLYGIC (talimogene laherparepvec/T-Vec; Amgen) was the first oncolytic virus approved by the US FDA and the European Commission (EC) for treating unresectable melanoma lesions. This therapy uses a genetically modified Herpes Simplex Virus Type 1 (HSV-1) to replicate within tumors and stimulate the immune system.

In 2021, DELYTACT (teserpaturev/G47∆; Daiichi Sankyo) received conditional approval in Japan as the first oncolytic virus for malignant glioma. This virus is distinguished by its triple mutation within the viral genome, which enhances its ability to replicate in tumor cells and activate the immune response.

Despite these significant achievements, ongoing development in oncolytic virotherapy is marked by active clinical trials conducted by leading companies such as Replimune, DNAtrix, and SillaJen. These efforts suggest a bright future for oncolytic virus therapy in treating various cancers globally.

Discover more about Oncolytic Virus Cancer Therapy treatment therapies in the pipeline @ https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Leading Companies Working in the Oncolytic Virus Cancer Therapy Market
Targovax
Replimune
Genelux Corporation
Candel Therapeutics
DNAtrix
SillaJen
Treovir
Lokon Pharma AB
Istari Oncology
CG Oncology
Amgen
Daiichio Sankyo
And others
To understand key companies related to the Oncolytic Virus Cancer Therapy Market, get a snapshot of the Oncolytic Virus Cancer Therapy Regulatory and Patent Analysis @ https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Oncolytic Virus Cancer Therapy Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Oncolytic Virus Cancer Therapy Companies: Targovax, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichio Sankyo, and others
Therapeutic Assessment: Oncolytic Virus Cancer Therapy current marketed and emerging therapies
Oncolytic Virus Cancer Therapy Market Dynamics: Oncolytic Virus Cancer Therapy market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Oncolytic Virus Cancer Therapy Market Access and Reimbursement
Table of Contents
1. Oncolytic Virus Cancer Therapy Market Key Insights
2. Oncolytic Virus Cancer Therapy Market Report Introduction
3. Oncolytic Virus Cancer Therapy Market Overview at a Glance
4. Oncolytic Virus Cancer Therapy Market Executive Summary
5. Disease Background and Overview
6. Oncolytic Virus Cancer Therapy Treatment and Management
7. Oncolytic Virus Cancer Therapy Epidemiology and Patient Population
8. Patient Journey
9. Oncolytic Virus Cancer Therapy Emerging Drugs
10. 7MM Oncolytic Virus Cancer Therapy Market Analysis
11. Oncolytic Virus Cancer Therapy Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Oncolytic Virus Cancer Therapy Market Drivers
15. Oncolytic Virus Cancer Therapy Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Trending Reports By DelveInsight:

Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market

Lebers Hereditary Optic Neuropathy Lhon Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market

Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market

Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market

Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market

Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market

Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market

Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market

Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market

Hypoplastic Left Heart Syndrome Hlhs Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market

Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market

Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market

Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market

Clinically Isolated Syndrome CIS Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market

Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market

Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market

Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market

Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market

Contact Us
Kritika Rehani
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.